Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 10998.145 | 0.8900 | 0.7668 | 0.9403 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 10998.145 | 0.9256 | 0.8422 | 0.9403 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 10998.145 | 0.8745 | 0.7342 | 0.9403 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 10998.145 | 0.9437 | 0.8805 | 0.9403 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 10998.145 | 1.0285 | 1.0607 | 0.9403 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 12206.145 | 0.9977 | 0.9947 | 0.8709 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 12206.145 | 0.9958 | 0.9903 | 0.8709 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 12206.145 | 1.0486 | 1.1120 | 0.8709 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 12206.145 | 1.0186 | 1.0429 | 0.8709 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 12206.145 | 0.9816 | 0.9578 | 0.8709 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 12206.145 | 1.0258 | 1.0594 | 0.8709 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 12206.145 | 0.9922 | 0.9822 | 0.8709 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 12206.145 | 1.0371 | 1.0855 | 0.8709 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 12206.145 | 1.0204 | 1.0468 | 0.8709 | |
| MDA-MB-157 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.000512 | uM | 12594.17 | 1.0483 | 1.0789 | 1.2180 | |
| MDA-MB-157 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.00256 | uM | 12594.17 | 1.0161 | 1.0264 | 1.2180 | |
| MDA-MB-157 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.0128 | uM | 12594.17 | 1.0098 | 1.0161 | 1.2180 | |
| MDA-MB-157 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.064 | uM | 12594.17 | 1.0147 | 1.0241 | 1.2180 | |
| MDA-MB-157 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.32 | uM | 12594.17 | 0.9956 | 0.9927 | 1.2180 | |
| MDA-MB-157 | TNBC | Basal B | Nilotinib | ABL | nRTK | 1.6 | uM | 12594.17 | 0.8948 | 0.8255 | 1.2180 | |
| MDA-MB-157 | TNBC | Basal B | Nilotinib | ABL | nRTK | 8 | uM | 12594.17 | 0.9672 | 0.9461 | 1.2180 | |
| MDA-MB-157 | TNBC | Basal B | Nilotinib | ABL | nRTK | 40 | uM | 12594.17 | 0.8882 | 0.8144 | 1.2180 | |
| MDA-MB-157 | TNBC | Basal B | Nilotinib | ABL | nRTK | 200 | uM | 12594.17 | 0.9972 | 0.9953 | 1.2180 | |
| MDA-MB-175-VII | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 10642.145 | 1.0541 | 1.3212 | 0.3537 | |
| MDA-MB-175-VII | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 10642.145 | 1.0089 | 1.0505 | 0.3537 |